Journal of diabetes and its complications最新文献

{"title":"The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: A meta-analysis of randomized controlled trials","authors":"Beatriz Austregésilo de Athayde De Hollanda Morais ,&nbsp;Vitória Martins Prizão ,&nbsp;Mariana de Moura de Souza ,&nbsp;Beatriz Ximenes Mendes ,&nbsp;Maria Luiza Rodrigues Defante ,&nbsp;Otavio Cosendey Martins ,&nbsp;Adriane Maria Rodrigues","doi":"10.1016/j.jdiacomp.2024.108834","DOIUrl":"10.1016/j.jdiacomp.2024.108834","url":null,"abstract":"<div><h3>Background</h3><p>The efficacy of GLP1 receptor agonists (GLP1-RAs) in treating polycystic ovarian syndrome (PCOS) remains unclear. While GLP1-RAs are known to promote weight loss in patients with diabetes and living with obesity, their impact on weight reduction and hormonal regulation in women with PCOS is understudied. Therefore, we aimed to assess the efficacy of GLP1-RAs in PCOS women living with obesity through a meta-analysis, comparing their effects to placebo.</p></div><div><h3>Hypothesis</h3><p>The use of GLP1-RAs in PCOS women living with obesity can reduce body mass index and waist circumference as well as improve hyperinsulinism, and hyperandrogenism as well as normalize total testosterone, total cholesterol and HOMA-IR markers in PCOS women living with obesity.</p></div><div><h3>Methods</h3><p>We systematically searched the PubMed, Cochrane Central, Scopus and Embase databases to identify randomized controlled trials (RCT) comparing GLP1-RAs versus placebo among women diagnosed with PCOS based on the Rotterdam Criteria. Our primary outcomes of interest included body mass index (BMI), triglycerides, waist circumference, total testosterone, total cholesterol, and HOMA-IR. We performed data extraction and quality assessment for studies that met the inclusion criteria. We pooled mean difference (MD) and 95 % confidence intervals (CI) with a random-effect model for continuous endpoints.</p></div><div><h3>Results</h3><p>We included 176 participants from four RCTs. Semaglutide and Liraglutide were used in 23 (13 %) and 103 (58 %) participants, respectively. GLP1-RAs use was associated with a significant reduction in waist circumference (MD: −5.16 cm; 95 % CI: −6.11 to −4.21; p ˂ 0.00001), body mass index (BMI) (MD: −2.42; 95 % CI: −3.10 to −1.74; p ˂ 0.00001), serum triglycerides (MD: −0.20; 95 % CI: −0.30 to −0.11; p ˂ 0.00001) and total testosterone levels (MD: −1.33; 95 % CI: −2.55 to −0.12; <em>p</em> = 0.03) when compared to placebo. There was no significant difference in total cholesterol (MD: −0.04; 95 % CI: −0.10 to 0.01; <em>p</em> = 0.15) and HOMA-IR (MD: −0.30; 95 % CI: −0.92 to 0.32; <em>p</em> = 0.35) levels. Adverse events information was available for 112 patients, where 49 had light side effects such as nausea and abdominal pain.</p></div><div><h3>Conclusion</h3><p>The use of GLP1-RAs demonstrates efficacy in reducing BMI, triglycerides, waist circumference and total testosterone. There was no significant difference in total cholesterol and HOMA-IR levels. These results signify its viability as a favourable treatment option for managing PCOS symptoms in women living with obesity.</p></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"38 10","pages":"Article 108834"},"PeriodicalIF":2.9,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142040589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"“Predicting diabetic kidney disease in youth with type 1 diabetes: Insights from genetic risk assessment”","authors":"Ferda Evin ,&nbsp;Tarık Kırkgöz ,&nbsp;Tahir Atik ,&nbsp;Güneş Ak ,&nbsp;Timur Köse ,&nbsp;Caner Kabasakal ,&nbsp;Behzat Özkan ,&nbsp;Samim Özen ,&nbsp;Şükran Darcan ,&nbsp;Damla Gökşen","doi":"10.1016/j.jdiacomp.2024.108833","DOIUrl":"10.1016/j.jdiacomp.2024.108833","url":null,"abstract":"<div><h3>Objective</h3><p>Diabetic kidney disease (DKD) is influenced by multiple factors, yet its precise progression mechanisms remain largely unclear. This study aimed to create a clinical risk-scoring system based on genetic polymorphisms in the AFF3, CARS, CERS2, ERBB4, GLRA3, RAET1L, TMPO, and ZMIZ1 genes.</p></div><div><h3>Methods</h3><p>The study included a DKD group diagnosed with diabetic kidney disease before age 18 and a WDC group matched by age, gender, and age at diabetes diagnosis. Genetic data and clinical data from diabetes diagnosis to moderately increased albuminuria (MIA) detection were compared between the groups.</p></div><div><h3>Results</h3><p>Among 43 DKD cases, 22 were girls and 21 were boys. At MIA diagnosis, mean body weight SDS was −0.24 ± 0.94, height SDS was 0.34 ± 1.15, and BMI SDS was −0.26 ± 0.94. Systolic blood pressure was at the 72nd percentile (2–99), and diastolic blood pressure was at the 74th percentile (33–99). Significant differences in rs267734, rs267738, and rs942263 polymorphisms were found between DKD and non-complication diabetic groups (13[30.2 %] vs 5[11.6 %], <em>p</em> = 0.034; 14[32.6 %] vs 5[11.6 %], <em>p</em> = 0.019; 26[60.5 %] vs 40[93 %], <em>p</em> &lt; 0.001).</p></div><div><h3>Conclusion</h3><p>Several factors were identified as significant in DKD onset, including low follow-up weight SDS, elevated diastolic blood pressure, presence of rs267734, and absence of rs942263 polymorphisms. The model demonstrated a specificity of 81.4 % and a sensitivity of 74.4 %.</p></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"38 11","pages":"Article 108833"},"PeriodicalIF":2.9,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142241135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contents/Barcode","authors":"","doi":"10.1016/S1056-8727(24)00166-1","DOIUrl":"10.1016/S1056-8727(24)00166-1","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"38 9","pages":"Article 108840"},"PeriodicalIF":2.9,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1056872724001661/pdfft?md5=af9edd360f0dece6f3b1f8797da7844d&pid=1-s2.0-S1056872724001661-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141979038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The optimal dose of metformin to control conversion to diabetes in patients with prediabetes: A meta-analysis","authors":"Xiaoyan Yi ,&nbsp;Yongliang Pan ,&nbsp;Huan Peng ,&nbsp;Mengru Ren ,&nbsp;Qin Jia ,&nbsp;Bing Wang","doi":"10.1016/j.jdiacomp.2024.108846","DOIUrl":"10.1016/j.jdiacomp.2024.108846","url":null,"abstract":"<div><h3>Aim</h3><p>This study aims to investigate the optimal dose of metformin for controlling the transition to diabetes in patients diagnosed with prediabetes.</p></div><div><h3>Methods</h3><p>We systematically searched randomized controlled trials (RCTs) in CNKI, Wanfang, VIP, SinoMed, Scopus, PubMed, Embase, Cochrane Library, Web of Science, and Cumulative Index to Nursing and Allied Health Literature (CINAHL) from inception to February 2024. Meta-analysis was conducted using RevMan 5.4 software.</p></div><div><h3>Results</h3><p>We included 25 randomized controlled trials comprising 2437 patients. The results of the meta-analysis revealed that compared to dose groups of 500 mg/d, 850 mg/d, 1000 mg/d, 1500 mg/d, 1700 mg/d, and 2000 mg/d, a dosage of 750 mg/d of metformin significantly reduced the incidence of diabetes in patients (risk ratio [RR] = 0.21, 95 % confidence interval [CI]: 0.11, 0.41; <em>p</em> &lt; 0.00001), lowered Postprandial Blood Glucose (PBG) (mean difference[MD] = −2.60, 95 % CI: −4.34, −0.86; <em>p</em> = 0.003), and promoted the normalization of blood glucose levels (RR = 2.13, 95 % CI: 1.68, 2.71; <em>p</em> &lt; 0.00001). Regarding safety evaluation, no significant differences were identified among the various dose groups. In contrast, the cohort receiving a daily dosage of 750 mg demonstrated the most pronounced decrease in the incidence of adverse reactions.</p></div><div><h3>Conclusion</h3><p>Based on the efficacy and safety evaluation results, our findings suggest that a daily dosage of 750 mg of metformin may represent the optimal dose for controlling the progression from pre-diabetes to diabetes.</p></div><div><h3>Registration</h3><p>PROSPERO registration ID: CRD42024538322.</p></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"38 10","pages":"Article 108846"},"PeriodicalIF":2.9,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142008881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors contributing to diabetic ketoacidosis readmission in hospital settings in the United States: A scoping review","authors":"Ryan Mohler,&nbsp;Kathryn Lotharius,&nbsp;Elijah Moothedan,&nbsp;Jake Goguen,&nbsp;Rishiraj Bandi,&nbsp;Ryan Beaton,&nbsp;Michelle Knecht,&nbsp;Maria C. Mejia,&nbsp;Milad Khoury,&nbsp;Lea Sacca","doi":"10.1016/j.jdiacomp.2024.108835","DOIUrl":"10.1016/j.jdiacomp.2024.108835","url":null,"abstract":"<div><h3>Background</h3><p>Hospitalization of patients with DKA creates a significant burden on the US healthcare system. While previous studies have identified multiple potential contributors, a comprehensive review of the factors leading to DKA readmissions within the US healthcare system has not been done. This scoping review aims to identify how access to care, treatment adherence, socioeconomic status, race, and ethnicity impact DKA readmission-related patient morbidity and mortality and contribute to the socioeconomic burden on the US healthcare system. Additionally, this study aims to integrate current recommendations to address this multifactorial issue, ultimately reducing the burden at both individual and organizational levels.</p></div><div><h3>Methods</h3><p>The PRISMA-SCR (Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews) was used as a reference checklist throughout this study. The Arksey and O'Malley methodology was used as a framework to guide this review. The framework methodology consisted of five steps: (1) Identify research questions; (2) Search for relevant studies; (3) Selection of studies relevant to the research questions; (4) Chart the data; (5) Collate, summarize, and report the results.</p></div><div><h3>Results</h3><p>A total of 15 articles were retained for analysis. Among the various social factors identified, those related to sex/gender (<em>n</em> = 9) and age (<em>n</em> = 9) exhibited the highest frequency. Moreover, race and ethnicity (<em>n</em> = 8) was another recurrent factor that appeared in half of the studies. Economic factors were also identified in this study, with patient insurance type having the highest frequency (<em>n</em> = 11). Patient income had the second highest frequency (<em>n</em> = 6). Multiple studies identified a link between patients of a specific race/ethnicity and decreased access to treatment. Insufficient patient education around DKA treatment was noted to impact treatment accessibility. Certain recommendations for future directions were highlighted as recurrent themes across included studies and encompassed patient education, early identification of DKA risk factors, and the need for a multidisciplinary approach using community partners such as social workers and dieticians to decrease DKA readmission rates in diabetic patients.</p></div><div><h3>Conclusion</h3><p>This study can inform future policy decisions to improve the accessibility, affordability, and quality of healthcare through evidence-based interventions for patients with DM following an episode of DKA.</p></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"38 10","pages":"Article 108835"},"PeriodicalIF":2.9,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141975769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comparative study of the relationship between time in range assessed by self-monitoring of blood glucose and continuous glucose monitoring with microalbuminuria outcome, HOMA-IR and HOMA-β test","authors":"Wei Cao ,&nbsp;Jing Zou ,&nbsp;Ming Gao ,&nbsp;Jianv Huang ,&nbsp;Yangyang Li ,&nbsp;Na Li ,&nbsp;Li Qian ,&nbsp;Ying Zhang ,&nbsp;Minjun Ji ,&nbsp;Yu Liu","doi":"10.1016/j.jdiacomp.2024.108831","DOIUrl":"10.1016/j.jdiacomp.2024.108831","url":null,"abstract":"<div><h3>Aims</h3><p>To compare the time in range (TIR) obtained from self-monitoring of blood glucose (SMBG) with that obtained from continuous glucose monitoring (CGM), and explore the relationship of TIR with microalbuminuria outcome, HOMA-IR and HOMA-β test.</p></div><div><h3>Methods</h3><p>We recruited 400 patients with type 2 diabetes to carry out blood glucose monitoring by both SMBG and CGM for 3 consecutive days. TIR, TAR, TBR and other blood glucose variation indices were calculated respectively through the glucose data achieved from SMBG and CGM. The HOMA-IR and HOMA-β test was evaluated by an oral glucose tolerance test. Urinary microalbumin-to-creatinine ratio completed in the laboratory.</p></div><div><h3>Results</h3><p>The median (25 %, 75 % quartile) of TIR_CGM and TIR_SMBG were 74.94(44.90, 88.04) and 70.83(46.88, 87.50) respectively, and there was no significant difference, <em>p</em> = 0.489; For every 1 % increase in TIR_CGM, the risk of microalbuminuria decreased by 1.6 % (95%CI:0.973, 0.995, <em>p</em> = 0.006) and for every 1 % increase in TIR_SMBG, the risk of microalbuminuria decreased by 1.3 % (95%CI:0.975, 0.999, <em>p</em> = 0.033). Stepwise multiple linear regression analysis showed an independent positive correlation between TIR (including TIR_CGM and TIR_SBMG) and LnDI30 and LnDI120 levels (<em>p</em> = 0.000).</p></div><div><h3>Conclusions</h3><p>The TIR calculated by SMBG was highly consistent with that reported by CGM and was significantly associated with the risk of microalbuminuria and the HOMA-β. Higher TIR quartiles were associated with lower incidence of microalbuminuria as well as higher lever of HOMA-β. For patients with limited CGM application, SMBG-derived TIR may be an alternative to CGM-derived TIR, to assess blood glucose control.</p></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"38 10","pages":"Article 108831"},"PeriodicalIF":2.9,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141964521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methylglyoxal induces death in human brain neuronal cells (SH-SY5Y), prevented by metformin and dapagliflozin","authors":"Samantha Victor-Sami,&nbsp;Ali Kamali-Roosta,&nbsp;Yousif A. Shamsaldeen","doi":"10.1016/j.jdiacomp.2024.108832","DOIUrl":"10.1016/j.jdiacomp.2024.108832","url":null,"abstract":"<div><p>Diabetes mellitus is a metabolic disorder caused by a dysfunction in insulin action or secretion, leading to an elevation in blood glucose levels. It is a highly prevalent condition and as a result, the NHS spends 10 % of its entire budget on diabetes mellitus care, that is equivalent to £10 billion a year. Diabetes mellitus has been linked with vascular and neurological complications which may be associated with the progression of neurodegeneration and Alzheimer's disease. Chronic hyperglycaemia increases the production of the reactive oxidant species (ROS) such as methylglyoxal (MGO). MGO has been linked with vascular complications, neuropathy and cytotoxicity. The main aim of this study was to investigate the potential beneficial effect of antidiabetic agents such as metformin and dapagliflozin on human brain neuronal cells (SH-SY5Y) treated with MGO. SH-SY5Y cells were cultured in DMEM/F12 media and subjected overnight incubation with one of the following treatment conditions: Control (untreated); MGO (1 μM); MGO (100 μM); metformin (100 μM) + MGO (100 μM); and dapagliflozin (10 μM) + MGO (100 μM). Several assays were conducted to explore the effect of the treatment groups on the SH-SY5Y cells. These included: MTT assay; LDH assay, peroxynitrite fluorescence assay, and laser scanning confocal microscopy. MGO (100 μM) led to significant cell injury and damage and significantly reduced the survival of the cells by approximately 50–75 %, associated with significant increase in peroxynitrite. The addition of metformin (100 μM) or dapagliflozin (10 μM) represented significant protective effects on the cells and prevented the cell damage caused by the high MGO concentration. As a result, the findings of this research reveal that MGO-induced cell damage may partly be mediated by the generation of peroxynitrite, while the antidiabetic agents such as metformin and dapagliflozin prevent brain cell death, which potentially may play prophylactic roles against the risk of dementia in diabetic patients.</p></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"38 9","pages":"Article 108832"},"PeriodicalIF":2.9,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1056872724001582/pdfft?md5=99ef1d6f4c1b2747b891b2cd9a246f74&pid=1-s2.0-S1056872724001582-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contents/Barcode","authors":"","doi":"10.1016/S1056-8727(24)00145-4","DOIUrl":"10.1016/S1056-8727(24)00145-4","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"38 8","pages":"Article 108819"},"PeriodicalIF":2.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1056872724001454/pdfft?md5=8c26ae5b2837ce2e465e251c46d7a857&pid=1-s2.0-S1056872724001454-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141949540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of sodium glucose co-transporter-2 inhibitors with risk of diabetic ketoacidosis among hospitalized patients: A multicentre cohort study","authors":"Shohinee Sarma ,&nbsp;Benazir Hodzic-Santor ,&nbsp;Afsaneh Raissi ,&nbsp;Michael Colacci ,&nbsp;Amol A. Verma ,&nbsp;Fahad Razak ,&nbsp;Mats C. Højbjerg Lassen ,&nbsp;Michael Fralick","doi":"10.1016/j.jdiacomp.2024.108827","DOIUrl":"10.1016/j.jdiacomp.2024.108827","url":null,"abstract":"<div><h3>Introduction</h3><p>Sodium glucose co-transporter-2 inhibitors (SGLT-2i) are increasingly being used among hospitalized patients. Our objective was to assess the risk of diabetic ketoacidosis (DKA) among hospitalized patients receiving an SGLT-2i.</p></div><div><h3>Research design and methods</h3><p>We conducted a multicentre cohort study of patients hospitalized at 19 hospitals. We included patients over 18 years of age who received an SGLT-2i or a dipeptidyl peptidase-4 inhibitor (DPP-4i) in hospital. The primary outcome was the risk of DKA during their hospitalization.</p></div><div><h3>Results</h3><p>61,517 patients received a DPP-4i and 11,061 received an SGLT-2i. The risk of inpatient DKA was 0.07 % (<em>N</em> = 41 events) among adults who received a DPP-4i and 0.18 % (<em>N</em> = 20 events) among adults who received an SGLT-2i; adjusted odds ratio of 3.30 (95 % CI: 1.85–5.72).</p></div><div><h3>Conclusions</h3><p>In hospitalized patients, the absolute risk of DKA was 0.2 %, which corresponded to a three-fold higher relative risk.</p></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"38 9","pages":"Article 108827"},"PeriodicalIF":2.9,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141889405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An online tool using clinical factors to estimate the probability of partial clinical remission of adult-onset Type 1 diabetes","authors":"Andrzej S. Januszewski ,&nbsp;Agata Grzelka-Wozniak ,&nbsp;Justyna Flotynska ,&nbsp;Alicia J. Jenkins ,&nbsp;Dorota A. Zozulinska-Ziolkiewicz ,&nbsp;Aleksandra A. Uruska","doi":"10.1016/j.jdiacomp.2024.108828","DOIUrl":"10.1016/j.jdiacomp.2024.108828","url":null,"abstract":"<div><p>A type 1 diabetes (T1D) diagnosis is often followed by a period of reduced exogenous insulin requirement, with acceptable glucose control, called partial clinical remission (pCR). Various criteria exist to define pCR, which is associated with better clinical outcomes.</p><p>We aimed to develop formulae and a related online calculator to predict the probability of pCR at 3- and 12-months post-T1D diagnosis.</p><p>We analysed data from 133 adults at their T1D diagnosis (mean ± SD age: 27 ± 6 yrs., HbA1c 11.1 ± 2.0 %, 98 ± 22 mmol/mol), 3- and 12-months later. All patients were enrolled in the prospective observational InLipoDiab1 study (<span><span>NCT02306005</span><svg><path></path></svg></span>). We compared four definitions of pCR: 1) stimulated C-peptide &gt;300 pmol/l; 2) insulin dose-adjusted HbA1c ≤9 %; 3) insulin dose &lt;0.3 IU/kg/24 h; and HbA1c ≤6.4 % (46 mmol/mol); and 4) insulin dose &lt;0.5 IU/kg/24 h and HbA1c &lt;7 % (53 mmol/mol). Using readily available demographics and clinical chemistry data exhaustive search methodology was used to model pCR probability.</p><p>There was low concordance between pCR definitions (kappa 0.10). The combination of age, HbA1c, diastolic blood pressure, triglycerides and smoking at T1D onset predicted pCR at 12-months with an area under the curve (AUC) = 0.87. HbA1c, triglycerides and insulin dose 3-mths post-diagnosis had an AUC = 0.89. A related calculator for pCR in adult-onset T1D is available at <span><span>http://www.bit.ly/T1D-partial-remission</span><svg><path></path></svg></span>.</p></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"38 9","pages":"Article 108828"},"PeriodicalIF":2.9,"publicationDate":"2024-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1056872724001545/pdfft?md5=034167d2b4b13fe8c2d9af3cc8265271&pid=1-s2.0-S1056872724001545-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141845802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}